Årsagerne til henvisningen var, at Tyskland ikke kunne godkende visse af indikationerne for behandling af cancer, da disse ikke var godkendt for bleomycin i Tyskland.
The grounds for the referral were that Germany was not in a position to accept some of the anti-cancer indications because they were not recognised as acceptable for bleomycin in the country.